These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 29270008

  • 1. Impact of mild to moderate COPD on feasibility and prognosis in non-small cell lung cancer patients who received chemotherapy.
    Omote N, Hashimoto N, Morise M, Sakamoto K, Miyazaki S, Ando A, Nakahara Y, Hasegawa Y.
    Int J Chron Obstruct Pulmon Dis; 2017; 12():3541-3547. PubMed ID: 29270008
    [Abstract] [Full Text] [Related]

  • 2. Impact of chemotherapy in the prognosis of non-small-cell lung cancer patients with severe to very severe COPD.
    Dong W, Du Y, Ma S.
    Int J Chron Obstruct Pulmon Dis; 2018; 13():3805-3812. PubMed ID: 30538442
    [Abstract] [Full Text] [Related]

  • 3. Impact of severe-to-very severe chronic obstructive pulmonary disease on the prognosis of patients with non-small cell lung cancer who received chemotherapy.
    Dong W, Zhu Y, Du Y, Wang L, Feng X, Ma S.
    Clin Respir J; 2020 Apr; 14(4):345-352. PubMed ID: 31876095
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Comparison of clinical characteristics and overall survival between spirometrically diagnosed chronic obstructive pulmonary disease (COPD) and non-COPD never-smoking stage I-IV non-small cell lung cancer patients.
    Lim JU, Yeo CD, Rhee CK, Kang HS, Park CK, Kim JS, Kim JW, Kim SJ, Yoon HK, Lee SH.
    Int J Chron Obstruct Pulmon Dis; 2019 Apr; 14():929-938. PubMed ID: 31118602
    [Abstract] [Full Text] [Related]

  • 6. Risk of mortality from cardiovascular and respiratory causes in patients with chronic obstructive pulmonary disease submitted to follow-up after lung resection for non-small cell lung cancer.
    Volpino P, Cangemi R, Fiori E, Cangemi B, De Cesare A, Corsi N, Di Cello T, Cangemi V.
    J Cardiovasc Surg (Torino); 2007 Jun; 48(3):375-83. PubMed ID: 17505444
    [Abstract] [Full Text] [Related]

  • 7. Prevalence of and risk factors for postoperative pulmonary complications after lung cancer surgery in patients with early-stage COPD.
    Kim ES, Kim YT, Kang CH, Park IK, Bae W, Choi SM, Lee J, Park YS, Lee CH, Lee SM, Yim JJ, Kim YW, Han SK, Yoo CG.
    Int J Chron Obstruct Pulmon Dis; 2016 Jun; 11():1317-26. PubMed ID: 27366059
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Impact of chronic obstructive pulmonary disease on postoperative recurrence in patients with resected non-small-cell lung cancer.
    Qiang G, Liang C, Xiao F, Yu Q, Wen H, Song Z, Tian Y, Shi B, Guo Y, Liu D.
    Int J Chron Obstruct Pulmon Dis; 2016 Jun; 11():43-9. PubMed ID: 26766906
    [Abstract] [Full Text] [Related]

  • 11. PIK3CA mutation as a distinctive genetic feature of non-small cell lung cancer with chronic obstructive pulmonary disease: A comprehensive mutational analysis from a multi-institutional cohort.
    Sawa K, Koh Y, Kawaguchi T, Kambayashi S, Asai K, Mitsuoka S, Kimura T, Yoshimura N, Yoshimoto N, Kubo A, Saka H, Matsumura A, Wanibuchi H, Yamamoto N, Nishiyama N, Hirata K.
    Lung Cancer; 2017 Oct; 112():96-101. PubMed ID: 29191607
    [Abstract] [Full Text] [Related]

  • 12. Comorbid pulmonary disease and risk of community-acquired pneumonia in COPD patients.
    Lin SH, Ji BC, Shih YM, Chen CH, Chan PC, Chang YJ, Lin YC, Lin CH.
    Int J Tuberc Lung Dis; 2013 Dec; 17(12):1638-44. PubMed ID: 24200282
    [Abstract] [Full Text] [Related]

  • 13. Effect of COPD on symptoms, quality of life and prognosis in patients with advanced non-small cell lung cancer.
    Yi YS, Ban WH, Sohng KY.
    BMC Cancer; 2018 Oct 29; 18(1):1053. PubMed ID: 30373585
    [Abstract] [Full Text] [Related]

  • 14. Personalized pulmonary rehabilitation and occupational therapy based on cardiopulmonary exercise testing for patients with advanced chronic obstructive pulmonary disease.
    Maekura R, Hiraga T, Miki K, Kitada S, Miki M, Yoshimura K, Yamamoto H, Kawabe T, Mori M.
    Int J Chron Obstruct Pulmon Dis; 2015 Oct 29; 10():1787-800. PubMed ID: 26366071
    [Abstract] [Full Text] [Related]

  • 15. Preoperative spirometry results as a determinant for long-term mortality after EVAR for AAA.
    Ohrlander T, Dencker M, Acosta S.
    Eur J Vasc Endovasc Surg; 2012 Jan 29; 43(1):43-7. PubMed ID: 22051733
    [Abstract] [Full Text] [Related]

  • 16. Comparison of survival of chronic obstructive pulmonary disease patients with or without a localized non-small cell lung cancer.
    Jeppesen SS, Hansen NG, Schytte T, Nielsen M, Hansen O.
    Lung Cancer; 2016 Oct 29; 100():90-95. PubMed ID: 27597286
    [Abstract] [Full Text] [Related]

  • 17. Overall survival of driver mutation-negative non-small cell lung cancer patients with COPD under chemotherapy compared to non-COPD non-small cell lung cancer patients.
    Lim JU, Yeo CD, Rhee CK, Kim YH, Park CK, Kim JS, Kim JW, Kim SJ, Yoon HK, Lee SH.
    Int J Chron Obstruct Pulmon Dis; 2018 Oct 29; 13():2139-2146. PubMed ID: 30034229
    [Abstract] [Full Text] [Related]

  • 18. Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small-cell lung cancer.
    Ajimizu H, Ozasa H, Sato S, Funazo T, Sakamori Y, Nomizo T, Kuninaga K, Ogimoto T, Hosoya K, Yamazoe M, Tsuji T, Yoshida H, Itotani R, Ueno K, Kim YH, Muro S, Hirai T.
    Sci Rep; 2021 Dec 08; 11(1):23677. PubMed ID: 34880386
    [Abstract] [Full Text] [Related]

  • 19. Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy.
    Koch A, Fohlin H, Sörenson S.
    J Thorac Oncol; 2009 Mar 08; 4(3):326-32. PubMed ID: 19155996
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.
    Ciuleanu T, Stelmakh L, Cicenas S, Miliauskas S, Grigorescu AC, Hillenbach C, Johannsdottir HK, Klughammer B, Gonzalez EE.
    Lancet Oncol; 2012 Mar 08; 13(3):300-8. PubMed ID: 22277837
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.